|2.||Urinary Tract Infections (Urinary Tract Infection)
|5.||Soft Tissue Infections
|1.||Lo, Wen-Tsung: 3 articles (08/2014 - 05/2004)|
|2.||Wang, Chih-Chien: 3 articles (08/2014 - 05/2004)|
|3.||Walker, Mark J: 2 articles (01/2015 - 08/2012)|
|4.||Davies, Mark R: 2 articles (01/2015 - 08/2012)|
|5.||Chen, Jonathan H K: 2 articles (01/2015 - 08/2012)|
|6.||Tse, Herman: 2 articles (01/2015 - 08/2012)|
|7.||Yuen, Kwok-Yung: 2 articles (01/2015 - 08/2012)|
|8.||Barnett, Timothy C: 2 articles (01/2015 - 08/2012)|
|9.||Dougan, Gordon: 2 articles (01/2015 - 08/2012)|
|10.||Chen, Shyi-Jou: 2 articles (08/2014 - 10/2009)|
|1.||Penicillins (Penicillin)FDA Link
08/01/1965 - "[Controlled studies on comparative results of the treatment of scarlet fever with various penicillin preparations]."
01/01/1962 - "Electrocardiographic studies in the postinfectious stage of penicillin-treated scarlet fever."
11/01/1953 - "Electrocardiographic studies in scarlet fever; an investigation with special reference to the effect of penicillin treatment."
04/01/1953 - "[Studies on antitoxic immunity in scarlet fever treated with penicillin in children]."
09/01/1950 - "[Studies of scarlet fever patients treated with penicillin]."
|2.||Erythromycin (Erycette)FDA LinkGeneric
03/01/1972 - "[Drug sensitivity of Streptococcus haemolyticus ecently isolated from patients with scarlet fever with special reference to the advent of an erythromycin-resistant strain]."
07/15/1954 - "[Erythromycin: results in scarlet fever therapy]."
08/01/2001 - "Outbreak of scarlet fever caused by an erythromycin-resistant Streptococcus pyogenes emm22 genotype strain in a day-care center."
07/01/2014 - "To investigate the antibiotic pattern and erythromycin-resistant genes of GAS isolates associated with acute tonsillitis and scarlet fever in Chengdu, southwestern China. "
01/01/1954 - "I. Controlled studies on the comparative efficacy of erythromycin and penicillin in scarlet fever."
01/01/1995 - "SY5555 was effective in 100% of scarlet fever, pharyngotonsillitis, pneumonia, otitis media, bacterial diarrhea, urinary tract infections and skin and soft tissue infections. "
01/01/1995 - "1. SY5555 was administered to 10 children with various bacterial infections (2 patients with acute tonsillitis, 2 with acute bronchitis, 1 with pharyngitis, 2 with scarlet fever, 1 with pertussis and 2 with urinary tract infections). "
02/01/1995 - "SY5555 in dry syrup (powder which is dissolved before use) or tablet form was given orally to 21 children with acute bacterial infections including 4 with acute pharyngitis, 5 with acute tonsillitis, 7 with acute bronchitis, 2 with acute gastroenteritis, 1 each with scarlet fever, acute lymphadenitis and urinary tract infection. "
02/01/1995 - "1. SY5555 dry syrup (powder which is dissolved before use) was administered to 25 patients with bacterial infections (6 cases of bronchitis, 2 cases of bronchopneumonia, 1 case of pertussis, 3 cases of scarlet fever, 5 cases of tonsillitis, 3 cases of urinary tract infections, 2 cases of staphylococcal scalded skin syndrome, 1 case of impetigo, 2 cases of purulent lymphadenitis). "
01/01/1995 - "2. Clinical studies SY5555 was administered to 45 patients with various infectious diseases (2 with acute pharyngitis, 8 with acute tonsillitis, 4 with lacunar tonsillitis, 3 each with acute bronchitis, pneumonia and pertussis, 7 with scarlet fever, 3 with impetigo contagiosa, 6 with acute urinary tract infections, 2 with balanoposthitis and 1 each with cervical lymphadenitis, S.S.S.S., vulvitis and acute colitis) at daily doses between 3.4-10 mg/kg, t.i.d., for 3-14 days. "
|4.||Cefadroxil (Duricef)FDA LinkGeneric
02/01/1981 - "Among 78 cases of scarlet fever from which beta-hemolytic Streptococcus was proven from swab liquid of palatal tonsil, 67 cases received cefadroxil at a daily dose of 30-49 mg/kg, and the bacteria turned to negative the next day of administration in 72 cases, 2 days later in 6 cases. "
02/01/1981 - "Cefadroxil was applied in 100 cases of scarlet fever. "
02/01/1981 - "Clinical effects were investigated on cefadroxil powder for syrup (containing 100 mg of cefadroxil per 1 g) for acute bacterial infections (mostly scarlet fever) in the field of pediatrics, and the results were obtained as follows. "
02/01/1981 - "[Therapeutic experience with cefadroxil syrup in acute infections, especially scarlet fever, in pediatric field (author's transl)]."
06/01/1981 - "Clinical efficacy was studied with cefadroxil powder for syrup in 35 pediatric patients including 20 acute tonsillitis and pharyngitis, 6 scarlet fever, 2 cervical lymphadenitis and 7 urinary tract infections. "
09/01/2009 - "The fitting efficacy of the ARIMA-GRNN combination model was better than the single ARIMA, which had practical value in the research on time series data such as the incidence of scarlet fever."
07/01/2013 - "The morbidity series of scarlet fever were retrieved to analyze and fit the combined mathematical model which comprised an autoregressive integrated moving average (ARIMA) model and a neural network. "
09/01/2009 - "Application of the 'single auto regressive integrated moving average (ARIMA) model' and the 'ARIMA-generalized regression neural network (GRNN) combination model' in the research of the incidence of scarlet fever. "
09/01/2009 - "[Comparison of predictive effect between the single auto regressive integrated moving average (ARIMA) model and the ARIMA-generalized regression neural network (GRNN) combination model on the incidence of scarlet fever]."
|6.||Diphtheria-Tetanus-Pertussis Vaccine (DPT Vaccine)IBA
|7.||Amoxicillin (Wymox)FDA LinkGeneric
|8.||biapenem (L 627)IBA
12/01/1926 - "STUDIES IN SCARLET FEVER: I. The Amount of Scarlatinal Toxin in the Blood of Patients with Scarlet Fever."
07/01/1997 - "Twenty-five throat isolates of Streptococcus pyogenes (GAS, group A streptococcus) available from 24 children, including 10 children with scarlet fever and 14 asymptomatic carriers, and one asymptomatic staff member were studied for the presence of genes encoding streptococcal pyrogenic exotoxin types A (speA), B (speB), and C (speC) and for protease activity. "
06/01/1989 - "Group A streptococcal pyrogenic exotoxin (scarlet fever toxin) type A and blastogen A are the same protein."
08/01/1987 - "Reference strains of Streptococcus pyogenes and strains from recent epidemics and sporadic cases of scarlet fever were examined for their ability to produce erythrogenic toxin type A (ET A) by ELISA and double immunodiffusion (Ouchterlony) using an anti-ET A antibody purified by affinity chromatography. "
09/01/1983 - "The high prevalence of erythrogenic, toxin-producing strains is difficult to reconcile with the epidemiologic behavior of scarlet fever; the variations may be due to quantitative differences in toxin production or to a shift from the early scarlet fever-associated strains that produce A toxin to the currently prevalent strains that produce B and C toxins. "
08/01/2014 - "This study retrospectively monitored the presence of pyrogenic exotoxin genes, the emm typing, and the susceptibility of macrolide drugs in Streptococcus pyogenes isolated from children diagnosed with scarlet fever and pharyngotonsillitis in northern Taiwan. "
08/01/2014 - "In isolates from patients with scarlet fever, the frequencies of pyrogenic exotoxin genes were 9.5% for speA, 81.0% for speB, 4.8% for speC, and 71.4% for speF. "
08/01/2014 - "Little information is available on the differences in frequency of pyrogenic exotoxin genes between strains of group A streptococci that cause scarlet fever and those that cause pharyngotonsillitis in children in Taiwan. "
03/01/2014 - "Scarlet fever is historically considered a toxin-mediated disease, dependent on the production of the exotoxins SpeA and SpeC, but a strict association between scarlet fever and these exotoxins is not always detected. "
03/01/2014 - "Scarlet fever is caused by a limited number of Streptococcus pyogenes lineages and is associated with the exotoxin genes ssa, speA and speC."
08/31/1924 - "Control injections in persons whose serums blanch the rash in scarlet fever cause no reaction. "
08/31/1924 - "A series of observations on the blood of patients acutely ill with scarlet fever has shown that a toxic substance can be demonstrated in the serum by means of intracutaneous injections of the serum in persons who have not had scarlet fever and whose serums fail to blanch the rash in scarlet fever. "
04/12/1969 - "[On the treatment of scarlet fever with injections of benzathine-penicillin combination preparations]."
06/01/1954 - "[Scarlet fever therapy with one or two injections of oily depot penicillin]."
11/01/1917 - "Repeated injections into the blood stream of streptococci and stapnylococci derived from cases of scarlet fever, and of Bacillus coli communior failed to produce typical glomerulonephritis even when immune antibodies could be demonstrated in the serum in high dilutions. "
06/01/1931 - "Tracheotomy in an Adult for Œdematous Laryngitis in Scarlet Fever."
06/01/1931 - "Tracheotomy in an Adult for OEdematous Laryngitis in Scarlet Fever."
01/01/2006 - "Korzeniowski's succesful surgical treatment of rhinolaryngological diseases, such as scarlet fever of ear, treatment of deaf-mutism, sinusitis paranasales, operations of jaws, plastic reconstruction of the palate, foreign bodies of larynx, tracheotomy in the tuberculosis of larynx, are described in some more detail."
|4.||Estrogen Replacement Therapy
12/01/2006 - "A reduced multiple myeloma risk was found among women who had used antilipid statin therapy [OR, 0.4; 95% confidence interval (95% CI), 0.2-0.8] or estrogen replacement therapy (OR, 0.6; 95% CI, 0.4-0.99) or who had a medical history of allergy (OR, 0.4; 95% CI, 0.3-0.7), scarlet fever (OR, 0.5; 95% CI, 0.2-0.9), or bursitis (OR, 0.4; 95% CI, 0.2-0.7). "
05/01/2004 - "A reduced risk was found for women who had scarlet fever or who had used estrogen replacement therapy, aspirin, medications for non-insulin dependent diabetes, HMG-CoA reductase inhibitors, or beta-adrenergic blocking agents. "